News und Analysen
![New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzJBRWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5cbb888b15fc1babe89717dad3b9d241825019eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure_main-405x.jpg?locale=de)
New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
Novocure (NASDAQ: NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption
![Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzJBRWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5cbb888b15fc1babe89717dad3b9d241825019eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure_main-405x.jpg?locale=de)
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Novocure is a global oncology company working to extend survival in some of
![Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPSIIIA
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today provides an update on clinical results and timelines
![Xencor Reports Fourth Quarter and Full Year 2021 Financial Results: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNElsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c4d0ef2109eb59269aca9850381b8fb5000d84e6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Xencor_RGB_fullcolor.jpg?locale=de)
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial
![STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2MrTHc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ea827a8a18ac48b4411e5b4a6acd688cf767d614/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/STAAR_Surgical_Logo_Primary_Lockup_-28Sunise_Teal-29.jpg?locale=de)
STAAR Surgical Reports Fourth Quarter and Full Year 2021 Results
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the
![Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd3Y2VlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--da0eacbff9577a155858aa3d7b56f66f5acf07fb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/amc.png?locale=de)
Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening
Agilent Technologies Inc. (NYSE: A) announced today that researchers from the QIMR Berghofer Medical Research Institute in Brisbane, Australia, collaborated with Agilent experts on a
![Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTRqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8c255f1cb7b73806f677f1d1d64e93866d2979a5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Clovis_Logo_Process_Color.jpg?locale=de)
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Company’s clinical development programs and regulatory and
![LivaNova Reports Fourth-Quarter and Full-Year 2021 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN01qRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--21a914cdc6fc0b7ffdd18c2667f61a9a3ee0c178/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LN-Logo-Main-PANTONE.jpg?locale=de)
LivaNova Reports Fourth-Quarter and Full-Year 2021 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021.
For the fourth quarter of
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2021
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care published form 20-F for the fiscal year 2021
![Agilent Reports First-Quarter Fiscal Year 2022 Financial Results:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOE9jVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--35d3dc71bc91537c00371e80355e9bfbbf3e14d0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/sw_wf.png?locale=de)
Agilent Reports First-Quarter Fiscal Year 2022 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the first quarter ended Jan. 31, 2022, an increase of 8% compared to the first quarter of 2021 and up 9% on a core(1)
![Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a keynote presentation by Lidia Fonseca, Chief Digital and Technology Officer, Executive Vice
![Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a keynote presentation by Lidia Fonseca, Chief Digital and Technology Officer, Executive Vice
![ICON Reports Fourth Quarter and Full Year 2021 Results: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWRYRVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--91b049194ccf9261ff5ab4a8879b7c494da2dc48/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ICON_Positive_logo_PNG_-28nostrap-29.jpg?locale=de)
ICON Reports Fourth Quarter and Full Year 2021 Results
ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today reported its financial results for the fourth quarter and full year ended December 31
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care setzt sich Klimaziele: Klimaneutralität bis 2040, Halbierung der CO2-Emissionen bis 2030
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care sets climate targets: Climate neutrality by 2040, CO2 emissions to fall 50% by 2030
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care delivers on 2021 guidance, targets return to earnings growth in 2022
DGAP-News: Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care erfüllt Prognose und strebt für 2022 Rückkehr zu Gewinnwachstum an
![ICON plc to Present at the 2022 Citi Healthcare Conference: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMWRYRVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--91b049194ccf9261ff5ab4a8879b7c494da2dc48/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ICON_Positive_logo_PNG_-28nostrap-29.jpg?locale=de)
ICON plc to Present at the 2022 Citi Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2022 Citi
![Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzhpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--38b3f45f170b11880f9bbfb3e14c3e180b77ea27/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Sangamo_logoTM.jpg?locale=de)
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after
![Quidel Reports Fourth Quarter and Full Year 2021 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Quidel Reports Fourth Quarter and Full Year 2021 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the
![Agilent Acquires Artificial Intelligence Technology to Enhance Lab Productivity:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1dOTWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--18ec7f0ddffe02914646ae92f3e6156744ef57fd/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-vertical-transparent.png?locale=de)
Agilent Acquires Artificial Intelligence Technology to Enhance Lab Productivity
Agilent Technologies Inc. (NYSE: A) today announced it has acquired advanced artificial intelligence (AI) technology developed by Virtual Control, an AI and machine learning software developer that
![DGAP-News: Gerresheimer AG: Gerresheimer accelerates growth and raises mid-term guidance](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Gerresheimer AG: Gerresheimer accelerates growth and raises mid-term guidance
![DGAP-News: Gerresheimer AG: Gerresheimer beschleunigt Wachstum und hebt mittelfristige Prognose an](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Gerresheimer AG: Gerresheimer beschleunigt Wachstum und hebt mittelfristige Prognose an
![Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN29sRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2c39f3b6129a12541932c63b90c23307b141ad6b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/puma_logo_JPEG.jpg?locale=de)
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 3, following release of its fourth quarter and